DUBLIN--(BUSINESS WIRE)--The "Alzheimer's Disease TherapeuticsAlzheimer's Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)" report has been added to ResearchAndMarkets.com's offering. 'Alzheimer\'s Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)' Alzheimer's disease Therapeutics Pipeline Analysis has 101 active drugs undergoing several stages of clinical trials. The Alzheimer's disease Therapeutics Pipeline is driven by an increasing gap of unmet need of effective therapeutics that can cure Alzheimer's disease. Additionally, life expectancy has increased due to various healthcare reforms in major economies such as the U.S., Japan, and China. This has resulted in a large geriatric population which is the age group most affected by the disease. Eisai, Biogen, Hoffmann-La Roche, AZTherapies, Cerecin, Neurotrope, AC Immune, Cassava Sciences, AB Science, Anavex Life Sciences, Athira Pharma, Denali Therapeutics Inc., and other notable companies are developing therapeutic candidates to improve the Alzheimer's Diagnosis and treatment scenario. The report analyses the Alzheimer's Disease Therapeutics in Pipeline by Molecule Type (Small Molecules, Monoclonal Antibody, Vaccine, DNA/RNA Based, Natural products, Gene Therapy, Cell Therapy, Others). The report analyses the Alzheimer's disease Therapeutics by Route of Administration (Oral, Intravenous, Intramuscular, Subcutaneous, Intrathecal, Intranasal, Other). The report analyses the Alzheimer's disease Therapeutics by Pipeline Phase (Phase I, Phase I/II, Phase II, Phase II/III, Phase III, Phase IV, Preclinical). The report analyses the Pain Management Drugs Market by Availability (Over the Counter (OTC), Prescription).
The Global Pain Management Drugs Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).
The key insights of the report have been presented through the leading company shares.
Also, the major, trends, drivers and challenges as well as Unmet Needs of the industry has been analysed in the report.
The companies analysed in the report include Eli-Lily & Co , Elsal Co., Ltd., BioVie, Johnson and Johnson, Otsuka Pharmaceutical Co., Ltd. H. Lundbeck A/S, Novartis, Cognition Therapeutics, Merck Sharp & Dohme LLC, Biogen. End Users (Hospitals and clinics)
Research and Development (R&D) Organizations
Government Bodies & Regulating Authorities
Investment Banks and Equity Firms
2.3 Market Ecosystem Factors
3.1 Data Collection Process
3.2 Market Size Calculation-Top-to-Bottom
4. Macro Economic Indicator Outlook
4.1 Global, Region wise GDP Growth
4.2 Global Medical Spending
4.3 Current Healthcare Expenditure
4.4 Pharmaceutical Spending/capita
5. Competitive Positioning
5.1 Companies' Product Positioning
5.2 Competitive positioning
6.3 Causes and Risk Factors
6.4 Diagnosis and Assessment
7. Therapeutics in Pipeline
9. Phase I therapeutics Overview
10. Phase I/II therapeutics Overview
10.2 PrimeProT/ PrimeMSKT
10.9 ACI-35.030/ JACI-35.054
11. Phase II therapeutics Overview
11.34 Flos gossypii flavonoids
11.35 Human Mesenchymal Stem cells (MSCs)
12. Phase II/III therapeutics Overview
13. Phase III therapeutics Overview
14. Phase IV therapeutics Overview
15. Preclinical Phase therapeutics Overview
16. Pipeline analysis, By molecule type
17. Pipeline analysis, By Route of Administration
For more information about this report visit https://www.researchandmarkets.com/r/wcw7f7